메뉴 건너뛰기




Volumn 29, Issue 11, 2011, Pages 993-1003

Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION THERAPY; CURE RATE; DRUG DISCOVERY; EUROPEAN UNION; HEPATITIS C; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; PATIENT POPULATION; PROTEASE INHIBITOR; RIBAVIRIN; SCIENTIFIC ADVANCES; SIDE EFFECT; TREATMENT DURATION;

EID: 80755159054     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2020     Document Type: Review
Times cited : (234)

References (121)
  • 1
    • 37349020028 scopus 로고    scopus 로고
    • Hepatitis C: A clinical review
    • DOI 10.1111/j.1601-0825.2007.01419.x
    • Modi, A.A. & Liang, T.J. Hepatitis C: a clinical review. Oral Dis. 14, 10-14 (2008). (Pubitemid 350293995)
    • (2008) Oral Diseases , vol.14 , Issue.1 , pp. 10-14
    • Modi, A.A.1    Liang, T.J.2
  • 3
    • 79953009968 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention and Department of Health and Human Services CDC and HHS
    • Centers for Disease Control and Prevention and Department of Health and Human Services. Hepatitis C fact sheet (CDC and HHS, 2010). 〈http://www. cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf〉
    • (2010) Hepatitis C Fact Sheet
  • 4
    • 73149113990 scopus 로고    scopus 로고
    • Public health impact of antiviral therapy for hepatitis C in the United States
    • Volk, M.L., Tocco, R., Saini, S. & Lok, A. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50, 1750-1755 (2009).
    • (2009) Hepatology , vol.50 , pp. 1750-1755
    • Volk, M.L.1    Tocco, R.2    Saini, S.3    Lok, A.4
  • 5
    • 77950611229 scopus 로고    scopus 로고
    • Institute of Medicine recommendations for the prevention and control of hepatitis B and C
    • Mitchell, A.E., Colvin, H.M. & Palmer Beasley, R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 51, 729-733 (2010).
    • (2010) Hepatology , vol.51 , pp. 729-733
    • Mitchell, A.E.1    Colvin, H.M.2    Palmer Beasley, R.3
  • 7
    • 0032934283 scopus 로고    scopus 로고
    • Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
    • DOI 10.1002/hep.510290124
    • Bonkovsky, H. & Woolley, J. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 29, 264-270 (1999). (Pubitemid 29024012)
    • (1999) Hepatology , vol.29 , Issue.1 , pp. 264-270
    • Bonkovsky, H.L.1    Wolley, M.2
  • 9
    • 33644520948 scopus 로고    scopus 로고
    • Therapy of hepatitis C: From empiricism to eradication
    • Pawlotsky, J.M. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43, S207-S220 (2006).
    • (2006) Hepatology , vol.43
    • Pawlotsky, J.M.1
  • 10
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis management, and treatment of hepatitis C: An update
    • Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3    Seeff, L.B.4
  • 11
    • 78650741799 scopus 로고    scopus 로고
    • Current therapies for chronic hepatitis C
    • Ferguson, M. Current therapies for chronic hepatitis C. Pharmacotherapy 31, 92-111 (2011).
    • (2011) Pharmacotherapy , vol.31 , pp. 92-111
    • Ferguson, M.1
  • 12
    • 34250679750 scopus 로고    scopus 로고
    • Epidemiology of hepatitis C virus infection
    • Alter, M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13, 2436-2441 (2007). (Pubitemid 46929498)
    • (2007) World Journal of Gastroenterology , vol.13 , Issue.17 , pp. 2436-2441
    • Alter, M.J.1
  • 14
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
    • (2002) N. Engl. J. Med. , vol.347 , pp. 975-982
    • Fried, M.W.1
  • 15
    • 33747797031 scopus 로고    scopus 로고
    • Treating viral hepatitis C: Efficacy, side effects, and complications
    • DOI 10.1136/gut.2005.076646
    • Manns, M., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects and complications. Gut 55, 1350-1359 (2006). (Pubitemid 44277369)
    • (2006) Gut , vol.55 , Issue.9 , pp. 1350-1359
    • Manns, M.P.1    Wedemeyer, H.2    Cornberg, M.3
  • 16
    • 84858446874 scopus 로고    scopus 로고
    • Hoffmann-La Roche, Providence, RI
    • Pegasys (prescribing information) (Hoffmann-La Roche, Providence, RI, 2011). 〈http://www.gene.com/gene/products/information/pegasys/pdf/pi. pdf〉
    • (2011) Pegasys (Prescribing Information)
  • 17
    • 84858449936 scopus 로고    scopus 로고
    • Merck & Co, Whitehouse Station, NJ, USA
    • Pegintron (prescribing information). (Merck & Co, Whitehouse Station, NJ, USA, 2011). 〈http://www.spfiles.com/pipeg-intron.pdf〉
    • (2011) Pegintron (Prescribing Information)
  • 18
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis, S.J. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
    • (2004) Ann. Intern. Med. , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1
  • 19
    • 65449152185 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    • erratum, 361 1516 2009
    • McHutchison, J.G. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009); erratum, 361, 1516 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 1827-1838
    • McHutchison, J.G.1
  • 20
    • 66949176133 scopus 로고    scopus 로고
    • Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results
    • Bacon, B.R. et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49, 1838-1846 (2009).
    • (2009) Hepatology , vol.49 , pp. 1838-1846
    • Bacon, B.R.1
  • 21
    • 65349129985 scopus 로고    scopus 로고
    • Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-?2b: A randomized trial
    • Jensen, D.M. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-?2b: a randomized trial. Ann. Intern. Med. 150, 528-540 (2009).
    • (2009) Ann. Intern. Med. , vol.150 , pp. 528-540
    • Jensen, D.M.1
  • 22
    • 67349172961 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    • Poynard, T. et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136, 1618-1628 (2009).
    • (2009) Gastroenterology , vol.136 , pp. 1618-1628
    • Poynard, T.1
  • 24
    • 80755161906 scopus 로고    scopus 로고
    • Outcome of sustained virological responders and non-responders in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    • Morgan, T.R. et al. Outcome of sustained virological responders and non-responders in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 50 Suppl, 357A-358A (2009).
    • (2009) Hepatology , vol.50 , Issue.SUPPL.
    • Morgan, T.R.1
  • 25
    • 77952704228 scopus 로고    scopus 로고
    • Sustained virologic response prevents the development of esophageal varices in compensated Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
    • Bruno, S. et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51, 2069-2076 (2010).
    • (2010) Hepatology , vol.51 , pp. 2069-2076
    • Bruno, S.1
  • 26
    • 79953745558 scopus 로고    scopus 로고
    • Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: The US Department of Veterans Affairs' experience
    • Backus, L. et al. Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: the US Department of Veterans Affairs' experience. Hepatology 52 Suppl, 428A (2010).
    • (2010) Hepatology , vol.52 , Issue.SUPPL.
    • Backus, L.1
  • 27
    • 0000163169 scopus 로고    scopus 로고
    • Flaviviridae the viruses and their replication
    • (eds. Knipe, D.M. et al.) Lippincott Williams & Wilkins, Philadelphia
    • Lindenbach, B.D. & Rice, C.M. Flaviviridae: the viruses and their replication. in Field's Virology, ed. 4. (eds. Knipe, D.M. et al.) 991-1041 (Lippincott Williams & Wilkins, Philadelphia, 2001).
    • (2001) Field's Virology , vol.4 , pp. 991-1041
    • Lindenbach, B.D.1    Rice, C.M.2
  • 28
    • 23944476834 scopus 로고    scopus 로고
    • Unravelling hepatitis C virus replication from genome to function
    • DOI 10.1038/nature04077
    • Lindenbach, B.D. & Rice, C.M. Unravelling hepatitis C virus replication: from genome to function. Nature 436, 933-938 (2005). (Pubitemid 41191668)
    • (2005) Nature , vol.436 , Issue.7053 , pp. 933-938
    • Lindenbach, B.D.1    Rice, C.M.2
  • 29
    • 84858437985 scopus 로고    scopus 로고
    • Vertex Pharmaceuticals
    • Incivek (US package insert) (Vertex Pharmaceuticals, 2011). 〈http://pi.vrtx.com/files/uspi-telaprevir.pdf〉
    • (2011) Incivek (US Package Insert)
  • 30
    • 84858440209 scopus 로고    scopus 로고
    • Vertex Pharmaceuticals
    • Incivek (Canada product monograph) (Vertex Pharmaceuticals, 2011). 〈http://pi.vrtx. com/files/canadapm-telaprevir-en.pdf〉.
    • (2011) Incivek (Canada Product Monograph)
  • 31
    • 84929133500 scopus 로고    scopus 로고
    • Tibotec, Beerse, Belgium
    • Incivo (EU summary of product characteristics) (Tibotec, Beerse, Belgium, 2011). 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002313/WC500115529.pdf〉.
    • (2011) Incivo (EU Summary of Product Characteristics)
  • 32
    • 84858444945 scopus 로고    scopus 로고
    • Mitsubishi Tanabe Pharma, Osaka, Japan
    • Telavic (Japan package insert). (Mitsubishi Tanabe Pharma, Osaka, Japan, 2011). 〈http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/eMTPC110926-TLV. pdf〉
    • (2011) Telavic (Japan Package Insert)
  • 33
    • 1842632416 scopus 로고    scopus 로고
    • Population-Based Hepatitis C Surveillance and Treatment in a National Managed Care Organization
    • Shatin, D., Schech, S.D., Patel, K. & McHutchison, J.G. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am. J. Manag. Care 10, 250-256 (2004). (Pubitemid 38480794)
    • (2004) American Journal of Managed Care , vol.10 , Issue.4 , pp. 250-256
    • Shatin, D.1    Schech, S.D.2    Patel, K.3    McHutchison, J.G.4
  • 35
    • 75149163334 scopus 로고    scopus 로고
    • Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression
    • Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T. & Jennings, L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513-521 (2010).
    • (2010) Gastroenterology , vol.138 , pp. 513-521
    • Davis, G.L.1    Alter, M.J.2    El-Serag, H.3    Poynard, T.4    Jennings, L.W.5
  • 36
    • 0036982198 scopus 로고    scopus 로고
    • Inhibitors of hepatitis C virus NS3.4A protease: An overdue line of therapy
    • Perni, R.B. & Kwong, A.D. Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy. Prog. Med. Chem. 39, 215-255 (2002).
    • (2002) Prog. Med. Chem. , vol.39 , pp. 215-255
    • Perni, R.B.1    Kwong, A.D.2
  • 37
    • 78650021698 scopus 로고    scopus 로고
    • Recent advances in hepatitis C virus treatment: Review of HCV protease inhibitor clinical trials
    • Chary, A. & Holodniy, M. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev. Recent Clin. Trials 5, 158-173 (2010).
    • (2010) Rev. Recent Clin. Trials , vol.5 , pp. 158-173
    • Chary, A.1    Holodniy, M.2
  • 38
    • 84939257725 scopus 로고    scopus 로고
    • Recent progress in the development of HCV protease inhibitors
    • (ed. De Clercq, E.) Wiley-VCH, Weinheim, Germany
    • Mani, N., Rao, B.G., Kieffer, T.L. & Kwong, A.D. Recent progress in the development of HCV protease inhibitors. in Antiviral Drug Strategies (ed. De Clercq, E.) 307-328 (Wiley-VCH, Weinheim, Germany, 2011).
    • (2011) Antiviral Drug Strategies , pp. 307-328
    • Mani, N.1    Rao, B.G.2    Kieffer, T.L.3    Kwong, A.D.4
  • 39
    • 79953905045 scopus 로고    scopus 로고
    • Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus
    • Morikawa, K. et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 18, 305-315 (2011).
    • (2011) J. Viral Hepat. , vol.18 , pp. 305-315
    • Morikawa, K.1
  • 40
    • 68249161340 scopus 로고    scopus 로고
    • Serine protease inhibitors as anti-hepatitis C virus agents
    • R eiser, M. & Timm, J. Serine protease inhibitors as anti-hepatitis C virus agents. Expert Rev. Anti Infect. Ther. 7, 537-547 (2009).
    • (2009) Expert Rev. Anti Infect. Ther. , vol.7 , pp. 537-547
    • Reiser, M.1    Timm, J.2
  • 41
    • 68649110912 scopus 로고    scopus 로고
    • A review of HCV protease inhibitors
    • Chen, K. & Niroge, F. A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs 10, 821-837 (2009).
    • (2009) Curr. Opin. Investig. Drugs , vol.10 , pp. 821-837
    • Chen, K.1    Niroge, F.2
  • 44
    • 78650988631 scopus 로고    scopus 로고
    • Mixing the right hepatitis C inhibitor cocktail
    • Gelman, A. & Glenn, J. Mixing the right hepatitis C inhibitor cocktail. Trends Mol. Med. 17, 34-46 (2011).
    • (2011) Trends Mol. Med. , vol.17 , pp. 34-46
    • Gelman, A.1    Glenn, J.2
  • 45
    • 79952804270 scopus 로고    scopus 로고
    • Promising targets for anti-hepatitis C virus agents
    • Yoshida, T., Kondoh, M. & Yagi, K. Promising targets for anti-hepatitis C virus agents. Curr. Med. Chem. 18, 1239-1244 (2011).
    • (2011) Curr. Med. Chem. , vol.18 , pp. 1239-1244
    • Yoshida, T.1    Kondoh, M.2    Yagi, K.3
  • 46
    • 78149425102 scopus 로고    scopus 로고
    • Antiviral therapy for hepatitis C virus: Beyond the standard of care
    • Delang, L., Coelmont, L. & Neyts, J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2, 826-866 (2010).
    • (2010) Viruses , vol.2 , pp. 826-866
    • Delang, L.1    Coelmont, L.2    Neyts, J.3
  • 47
    • 0028908783 scopus 로고
    • Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase
    • Bartenschlager, R., Ahlborn-Laake, L., Yasargil, K., Mous, J. & Jacobsen, H. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J. Virol. 69, 198-205 (1995). (Pubitemid 24378794)
    • (1995) Journal of Virology , vol.69 , Issue.1 , pp. 198-205
    • Bartenschlager, R.1    Ahlborn-Laake, L.2    Yasargil, K.3    Mous, J.4    Jacobsen, H.5
  • 50
    • 0030592514 scopus 로고    scopus 로고
    • The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
    • DOI 10.1016/S0092-8674(00)81350-1
    • Love, R.A. et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331-342 (1996). (Pubitemid 26359010)
    • (1996) Cell , vol.87 , Issue.2 , pp. 331-342
    • Love, R.A.1    Parge, H.E.2    Wickersham, J.A.3    Hostomsky, Z.4    Habuka, N.5    Moomaw, E.W.6    Adachi, T.7    Hostomska, Z.8
  • 52
    • 0031789165 scopus 로고    scopus 로고
    • Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease
    • Taremi, S.S. et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7, 2143-2149 (1998). (Pubitemid 28495801)
    • (1998) Protein Science , vol.7 , Issue.10 , pp. 2143-2149
    • Taremi, S.S.1    Beyer, B.2    Maher, M.3    Yao, N.4    Prosise, W.5    Weber, P.C.6    Malcolm, B.A.7
  • 53
    • 0033571623 scopus 로고    scopus 로고
    • Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase
    • DOI 10.1016/S0969-2126(00)80025-8
    • Yao, N., Reichert, P., Taremi, S.S., Prosise, W.W. & Weber, P.C. Molecular views of the viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7, 1353-1363 (1999). (Pubitemid 29529876)
    • (1999) Structure , vol.7 , Issue.11 , pp. 1353-1363
    • Yao, N.1    Reichert, P.2    Taremi, S.S.3    Prosise, W.W.4    Weber, P.C.5
  • 54
    • 0036835773 scopus 로고    scopus 로고
    • Hepatitis C virus replicons: Potential role for drug development
    • DOI 10.1038/nrd942
    • Bartenschlager, R. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1, 911-916 (2002). (Pubitemid 37361585)
    • (2002) Nature Reviews Drug Discovery , vol.1 , Issue.11 , pp. 911-916
    • Bartenschlager, R.1
  • 57
    • 84885968342 scopus 로고    scopus 로고
    • Discovery and development of telaprevir
    • (ed., Kazmierski, W.) John Wiley & Sons
    • Grillot, A. et al. Discovery and development of telaprevir. in Antiviral Drugs: from Basic Discovery through Clinical Trials (ed., Kazmierski, W.) 209-224 (John Wiley & Sons, 2010.)
    • (2010) Antiviral Drugs: From Basic Discovery Through Clinical Trials , pp. 209-224
    • Grillot, A.1
  • 58
    • 15944372847 scopus 로고    scopus 로고
    • Expression of HCV protease in mouse liver results in liver injury which can be inhibited by VX-950, a Vertex HCV protease inhibitor
    • Kalkeri, G. et al. Expression of HCV protease in mouse liver results in liver injury which can be inhibited by VX-950, a Vertex HCV protease inhibitor. Hepatology 40 Suppl, 281A (2004).
    • (2004) Hepatology , vol.40 , Issue.SUPPL.
    • Kalkeri, G.1
  • 59
    • 24944472318 scopus 로고    scopus 로고
    • Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection
    • Chen, S.H. & Tan, S.L. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr. Med. Chem. 12, 2317-2342 (2005).
    • (2005) Curr. Med. Chem. , vol.12 , pp. 2317-2342
    • Chen, S.H.1    Tan, S.L.2
  • 60
    • 33744457959 scopus 로고    scopus 로고
    • Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease
    • Lin, C., Kwong, A.D. & Perni, R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 6, 3-16 (2006). (Pubitemid 43796632)
    • (2006) Infectious Disorders - Drug Targets , vol.6 , Issue.1 , pp. 3-16
    • Lin, C.1    Kwong, A.D.2    Perni, R.B.3
  • 65
    • 0030871616 scopus 로고    scopus 로고
    • Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: Elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping
    • DOI 10.1021/bi963054n
    • Landro, J.A. et al. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry 36, 9340-9348 (1997). (Pubitemid 27346971)
    • (1997) Biochemistry , vol.36 , Issue.31 , pp. 9340-9348
    • Landro, J.A.1    Raybuck, S.A.2    Luong, Y.P.C.3    O'Malley, E.T.4    Harbeson, S.L.5    Morgenstern, K.A.6    Rao, G.7    Livingston, D.J.8
  • 69
    • 9644275435 scopus 로고    scopus 로고
    • Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells
    • DOI 10.1128/AAC.48.12.4784-4792.2004
    • Lin, K., Kwong, A.D. & Lin, C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother. 48, 4784-4792 (2004). (Pubitemid 39577685)
    • (2004) Antimicrobial Agents and Chemotherapy , vol.48 , Issue.12 , pp. 4784-4792
    • Lin, K.1    Kwong, A.D.2    Lin, C.3
  • 70
    • 0037471233 scopus 로고    scopus 로고
    • Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection
    • Tsantrizos, Y.S. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. 42, 1355-1360 (2003).
    • (2003) Angew. Chem. , vol.42 , pp. 1355-1360
    • Tsantrizos, Y.S.1
  • 73
    • 34848881891 scopus 로고    scopus 로고
    • Ultra-Rapid Cardiotoxicity of the Hepatitis C Virus Protease Inhibitor BILN 2061 in the Urokinase-Type Plasminogen Activator Mouse
    • DOI 10.1053/j.gastro.2007.07.007, PII S0016508507013078
    • Vanwolleghem, T. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133, 1144-1155 (2007). (Pubitemid 47494454)
    • (2007) Gastroenterology , vol.133 , Issue.4 , pp. 1144-1155
    • Vanwolleghem, T.1    Meuleman, P.2    Libbrecht, L.3    Roskams, T.4    De Vos, R.5    Leroux-Roels, G.6
  • 74
    • 33744454875 scopus 로고    scopus 로고
    • VX950: A tight binding HCV protease inhibitor with a superior sustained inhibitory response in HCV replicon cells
    • Lin, K. et al. VX950: a tight binding HCV protease inhibitor with a superior sustained inhibitory response in HCV replicon cells. Hepatology 38 Suppl, 222 (2003).
    • (2003) Hepatology , vol.38 , Issue.SUPPL. , pp. 222
    • Lin, K.1
  • 75
    • 33646446894 scopus 로고    scopus 로고
    • VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells
    • Lin, K., Perni, R.B., Kwong, A.D. & Lin, C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50, 1813-1822 (2006).
    • (2006) Antimicrob. Agents Chemother. , vol.50 , pp. 1813-1822
    • Lin, K.1    Perni, R.B.2    Kwong, A.D.3    Lin, C.4
  • 76
    • 0031024171 scopus 로고    scopus 로고
    • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    • DOI 10.1016/S0169-409X(96)00423-1, PII S0169409X96004231
    • Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997). (Pubitemid 27046991)
    • (1997) Advanced Drug Delivery Reviews , vol.23 , Issue.1-3 , pp. 3-25
    • Lipinski, C.A.1    Lombardo, F.2    Dominy, B.W.3    Feeney, P.J.4
  • 77
    • 0035897584 scopus 로고    scopus 로고
    • Amorphous pharmaceutical solids: Preparation, characterization and stabilization
    • DOI 10.1016/S0169-409X(01)00098-9, PII S0169409X01000989
    • Yu, L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48, 27-42 (2001). (Pubitemid 32454482)
    • (2001) Advanced Drug Delivery Reviews , vol.48 , Issue.1 , pp. 27-42
    • Yu, L.1
  • 78
    • 84858446501 scopus 로고    scopus 로고
    • Anonymous, International Conference on Harmonization Guidance
    • Anonymous. Stability testing of new drug substances and products (Q1A(R2) (International Conference on Harmonization Guidance, 2003). 〈http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm128204. pdf〉
    • (2003) Stability Testing of New Drug Substances and Products (Q1A(R2)
  • 80
    • 0033834092 scopus 로고    scopus 로고
    • Need for validation of clinical decision aids: Use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C
    • Imperiale, T.F., Said, A.T., Cummings, O.W. & Born, L.J. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am. J. Gastroenterol. 95, 2328-2332 (2000).
    • (2000) Am. J. Gastroenterol. , vol.95 , pp. 2328-2332
    • Imperiale, T.F.1    Said, A.T.2    Cummings, O.W.3    Born, L.J.4
  • 84
    • 46149127335 scopus 로고    scopus 로고
    • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
    • Lawitz, E. et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol. 49, 163-169 (2008).
    • (2008) J. Hepatol. , vol.49 , pp. 163-169
    • Lawitz, E.1
  • 85
    • 65449171953 scopus 로고    scopus 로고
    • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    • Hézode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 1839-1850
    • Hézode, C.1
  • 86
    • 77950817619 scopus 로고    scopus 로고
    • Telaprevir for previously treated chronic HCV infection
    • erratum 362 1647
    • McHutchison, J. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303; erratum, 362, 1647 (2009).
    • (2009) N. Engl. J. Med. , vol.362 , pp. 1292-1303
    • McHutchison, J.1
  • 87
    • 0036830454 scopus 로고    scopus 로고
    • Side effects of therapy of hepatitis C and their management
    • DOI 10.1053/jhep.2002.36810
    • Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36, S237-S244 (2002). (Pubitemid 35253486)
    • (2002) Hepatology , vol.36 , Issue.5
    • Fried, M.W.1
  • 88
    • 18844374423 scopus 로고    scopus 로고
    • How does ribavirin improve interferon-alpha response rates in hepatitis C virus infection?
    • Pawlotsky, J.M. How does ribavirin improve interferon-alpha response rates in hepatitis C virus infection? J. Hepatol. 42, 951-953 (2005).
    • (2005) J. Hepatol. , vol.42 , pp. 951-953
    • Pawlotsky, J.M.1
  • 89
    • 0031773286 scopus 로고    scopus 로고
    • Combination therapy of chronic hepatitis C: An important step but not the final goal!
    • DOI 10.1016/S0168-8278(98)80133-5
    • Wedemeyer, H., Caselmann, W.H. & Manns, M.P. Combination therapy of chronic hepatitis C: an important step but not the final goal! J. Hepatol. 29, 1010-1014 (1998). (Pubitemid 28559075)
    • (1998) Journal of Hepatology , vol.29 , Issue.6 , pp. 1010-1014
    • Wedemeyer, H.1    Caselmann, W.H.2    Manns, M.P.3
  • 91
    • 77950203857 scopus 로고    scopus 로고
    • Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
    • Kieffer, T., Kwong, A. & Picchio, G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 65, 202-212 (2010).
    • (2010) J. Antimicrob. Chemother. , vol.65 , pp. 202-212
    • Kieffer, T.1    Kwong, A.2    Picchio, G.3
  • 94
    • 37849032050 scopus 로고    scopus 로고
    • Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease
    • Zhou, Y. et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52, 110-120 (2008).
    • (2008) Antimicrob. Agents Chemother. , vol.52 , pp. 110-120
    • Zhou, Y.1
  • 96
    • 79951630741 scopus 로고    scopus 로고
    • Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: Interim analysis of the EXTEND study
    • Zeuzem, S. et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 52, 436A (2010).
    • (2010) Hepatology , vol.52
    • Zeuzem, S.1
  • 97
    • 3543125970 scopus 로고    scopus 로고
    • A long-term latent reservoir for HIV-1: Discovery and clinical implications
    • DOI 10.1093/jac/dkh292
    • Siliciano, J.D. & Siliciano, R.F. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54, 6-9 (2004). (Pubitemid 39028960)
    • (2004) Journal of Antimicrobial Chemotherapy , vol.54 , Issue.1 , pp. 6-9
    • Siliciano, J.D.1    Siliciano, R.F.2
  • 98
    • 51749123143 scopus 로고    scopus 로고
    • Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects
    • Bartels, D.J. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800-807 (2008).
    • (2008) J. Infect. Dis. , vol.198 , pp. 800-807
    • Bartels, D.J.1
  • 99
    • 79952308832 scopus 로고    scopus 로고
    • Clinical virology results from telaprevir Phase 3 study ADVANCE
    • Kieffer, T. et al. Clinical virology results from telaprevir Phase 3 study ADVANCE. Hepatology 52 Suppl, 879A (2010).
    • (2010) Hepatology , vol.52 , Issue.SUPPL.
    • Kieffer, T.1
  • 100
    • 68549092559 scopus 로고    scopus 로고
    • Rapid decrease of wild-type hepatitis C virus on telaprevir treatment
    • Adiwijaya, B.S. et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir. Ther. 14, 591-595 (2009).
    • (2009) Antivir. Ther. , vol.14 , pp. 591-595
    • Adiwijaya, B.S.1
  • 101
    • 77954598121 scopus 로고    scopus 로고
    • A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants
    • Adiwijaya, B.S. et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLOS Comput. Biol. 6, e1000745 (2010).
    • (2010) PLOS Comput. Biol. , vol.6
    • Adiwijaya, B.S.1
  • 102
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson, I.M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1
  • 103
    • 80052826527 scopus 로고    scopus 로고
    • Response-guided telaprevir combination treatment for hepatitis C virus infection
    • Sherman, K.E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014-1024 (2011).
    • (2011) N. Engl. J. Med. , vol.365 , pp. 1014-1024
    • Sherman, K.E.1
  • 104
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , pp. 2417-2428
    • Zeuzem, S.1
  • 105
    • 79952308832 scopus 로고    scopus 로고
    • Clinical virology results from telaprevir phase 3 study ADVANCE
    • Kieffer, T. et al. Clinical virology results from telaprevir phase 3 study ADVANCE. Hepatology 52 Suppl, 879A (2010).
    • (2010) Hepatology , vol.52 , Issue.SUPPL.
    • Kieffer, T.1
  • 106
    • 80053512471 scopus 로고    scopus 로고
    • Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response rates in treatment-naive patients regardless of race or ethnicity
    • Dusheiko, G.M. et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response rates in treatment-naive patients regardless of race or ethnicity. J. Hepatol. 54 Suppl 1, S167-S168 (2011).
    • (2011) J. Hepatol. , vol.54 , Issue.SUPPL. 1
    • Dusheiko, G.M.1
  • 107
    • 80755151889 scopus 로고    scopus 로고
    • Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage
    • Marcellin, P. et al. Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage. J. Hepatol. 54 Suppl 1, 1348A (2011).
    • (2011) J. Hepatol. , vol.54 , Issue.SUPPL. 1
    • Marcellin, P.1
  • 108
    • 84858442180 scopus 로고    scopus 로고
    • Hoffmann-La Roche, Providence, RI
    • Copegus (prescribing information) (Hoffmann-La Roche, Providence, RI, 2010). 〈http://www.gene.com/gene/products/information/pegasys/pdf/copegus- pi.pdf〉
    • (2010) Copegus (Prescribing Information)
  • 109
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
    • Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L. & Seeff, L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-1444 (2011).
    • (2011) Hepatology , vol.54 , pp. 1433-1444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3    Thomas, D.L.4    Seeff, L.B.5
  • 110
    • 0024509701 scopus 로고
    • Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
    • Choo, Q.L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
    • (1989) Science , vol.244 , pp. 359-362
    • Choo, Q.L.1
  • 112
    • 0033539482 scopus 로고    scopus 로고
    • Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
    • Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 96, 13034-13039 (1999).
    • (1999) Proc. Natl. Acad. Sci. USA , vol.96 , pp. 13034-13039
    • Bressanelli, S.1
  • 113
    • 0034687231 scopus 로고    scopus 로고
    • Prediction of drug absorption using multivariate statistics
    • E gan, W.J., Merz, K.M. Jr. & Baldwin, J.J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43, 3867-3877 (2000).
    • (2000) J. Med. Chem. , vol.43 , pp. 3867-3877
    • Gan W J, E.1    Merz Jr., K.M.2    Baldwin, J.J.3
  • 114
    • 80055062466 scopus 로고    scopus 로고
    • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    • published online doi:10.1002/hep.24549 (24 August
    • Muir, A. et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology published online, doi:10.1002/hep.24549 (24 August 2011).
    • (2011) Hepatology
    • Muir, A.1
  • 115
    • 79251554986 scopus 로고    scopus 로고
    • Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C
    • Marcellin, P. et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology 140, 459-468 (2011).
    • (2011) Gastroenterology , vol.140 , pp. 459-468
    • Marcellin, P.1
  • 116
    • 65649142019 scopus 로고    scopus 로고
    • Telaprevir a promising protease inhibitor for the treatment of hepatitis C virus infection
    • Gentile, I., Viola, C., Borgia, F., Castaldo, G. & Borgia, G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr. Med. Chem. 16, 1115-1121 (2009).
    • (2009) Curr. Med. Chem. , vol.16 , pp. 1115-1121
    • Gentile, I.1    Viola, C.2    Borgia, F.3    Castaldo, G.4    Borgia, G.5
  • 117
    • 65449127754 scopus 로고    scopus 로고
    • A step forward in therapy for hepatitis C
    • Hoofnagle, J.H. A step forward in therapy for hepatitis C. N. Engl. J. Med. 360, 1899-1901 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 1899-1901
    • Hoofnagle, J.H.1
  • 118
    • 67650700013 scopus 로고    scopus 로고
    • Telaprevir hope on the horizon, getting closer
    • Weisberg, I.S. & Jacobson, I.M. Telaprevir: hope on the horizon, getting closer. Clin. Liver Dis. 13, 441-452 (2009).
    • (2009) Clin. Liver Dis. , vol.13 , pp. 441-452
    • Weisberg, I.S.1    Jacobson, I.M.2
  • 119
    • 79955669252 scopus 로고    scopus 로고
    • A new standard of care for the treatment of chronic HCV infection
    • Hofmann, W.P. & Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 8, 257-264 (2011).
    • (2011) Nat. Rev. Gastroenterol. Hepatol. , vol.8 , pp. 257-264
    • Hofmann, W.P.1    Zeuzem, S.2
  • 120
    • 78650805019 scopus 로고    scopus 로고
    • The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients
    • Nelson, D.R. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int. 31, 53-57 (2011).
    • (2011) Liver Int. , vol.31 , pp. 53-57
    • Nelson, D.R.1
  • 121
    • 84858450910 scopus 로고    scopus 로고
    • Antiviral Drugs Advisory Committee NDA 201-917 (Cambridge, MA, Vertex Pharmaceuticals Incorporated. 4-28-2011)
    • Antiviral Drugs Advisory Committee. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C: briefing document. NDA 201-917. (2011). (Cambridge, MA, Vertex Pharmaceuticals Incorporated. 4-28-2011) . 〈http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562. pdf〉
    • (2011) Telaprevir 375-mg Film-coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C: Briefing Document


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.